## Wei-Jun Wei

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8708144/publications.pdf

Version: 2024-02-01

		361045	344852
52	1,466 citations	20	36
papers	citations	h-index	g-index
F.2	<b>5</b> 2	<b>5</b> 2	2220
53	53	53	2229
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	ImmunoPET imaging of hematological malignancies: From preclinical promise to clinical reality. Drug Discovery Today, 2022, 27, 1196-1203.	3.2	9
2	Annotating BCMA Expression in Multiple Myelomas. Molecular Pharmaceutics, 2022, 19, 3492-3501.	2.3	7
3	Annotating CD38 Expression in Multiple Myeloma with [ <sup>18</sup> F]F–Nb1053. Molecular Pharmaceutics, 2022, 19, 3502-3510.	2.3	10
4	GPC3-targeted immunoPET imaging of hepatocellular carcinomas. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2682-2692.	3.3	23
5	Engineering nanobodies for next-generation molecular imaging. Drug Discovery Today, 2022, 27, 1622-1638.	3.2	16
6	Molecular Imaging of Renal Cell Carcinoma in Precision Medicine. Molecular Pharmaceutics, 2022, 19, 3457-3470.	2.3	5
7	PET Imaging of Lung Cancers in Precision Medicine: Current Landscape and Future Perspective. Molecular Pharmaceutics, 2022, 19, 3471-3483.	2.3	4
8	Single-Domain Antibody Theranostics on the Horizon. Journal of Nuclear Medicine, 2022, 63, 1475-1479.	2.8	14
9	ImmunoPET imaging of multiple myeloma with [68Ga]Ga-NOTA-Nb1053. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2749-2760.	3.3	34
10	ImmunoPET/NIRF/Cerenkov multimodality imaging of ICAM-1 in pancreatic ductal adenocarcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2737-2748.	3.3	14
11	ImmunoPET imaging of human CD8+ T cells with novel 68Ga-labeled nanobody companion diagnostic agents. Journal of Nanobiotechnology, 2021, 19, 42.	4.2	30
12	Next-Generation Molecular Imaging of Thyroid Cancer. Cancers, 2021, 13, 3188.	1.7	6
13	Myofibrosarcoma infiltrating pulmonary arteries diagnosed on 18F-FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 1429.	3.3	O
14	Advancing the diagnosis of epithelioid hemangioendothelioma by F-FDG PET/CT. American Journal of Nuclear Medicine and Molecular Imaging, 2021, 11, 230-232.	1.0	0
15	Tissue Factorâ€Targeted ImmunoPET Imaging and Radioimmunotherapy of Anaplastic Thyroid Cancer. Advanced Science, 2020, 7, 1903595.	5.6	22
16	ImmunoPET: Concept, Design, and Applications. Chemical Reviews, 2020, 120, 3787-3851.	23.0	263
17	Development and characterization of CD54-targeted immunoPET imaging in solid tumors. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2765-2775.	3.3	15
18	ImmunoPET Imaging of TIMâ€3 in Murine Melanoma Models. Advanced Therapeutics, 2020, 3, 2000018.	1.6	12

#	Article	IF	CITATIONS
19	Molecular imaging of β-cells: diabetes and beyond. Advanced Drug Delivery Reviews, 2019, 139, 16-31.	6.6	42
20	A Preliminary Study of Ankle Single Photon Emission Computed Tomography/Computed Tomography in Patients With Bony Impingement Syndrome: Association With the Visual Analogue Scale Pain Score. Journal of Foot and Ankle Surgery, 2019, 58, 434-440.	0.5	8
21	Can pretreatment 18F-FDG PET tumor texture features predict the outcomes of osteosarcoma treated by neoadjuvant chemotherapy?. European Radiology, 2019, 29, 3945-3954.	2.3	22
22	Programmed Cell Death–Ligand 1 Overexpression in Thyroid Cancer. Endocrine Practice, 2019, 25, 279-286.	1.1	16
23	CD146â€Targeted Multimodal Imageâ€Guided Photoimmunotherapy of Melanoma. Advanced Science, 2019, 6, 1801237.	5.6	42
24	Exploiting Nanomaterialâ€Mediated Autophagy for Cancer Therapy. Small Methods, 2019, 3, 1800365.	4.6	25
25	Targeting autophagy in thyroid cancers. Endocrine-Related Cancer, 2019, 26, R181-R194.	1.6	18
26	Dual-labeled pertuzumab for multimodality image-guided ovarian tumor resection. American Journal of Cancer Research, 2019, 9, 1454-1468.	1.4	11
27	HER2-targeted multimodal imaging of anaplastic thyroid cancer. American Journal of Cancer Research, 2019, 9, 2413-2427.	1.4	10
28	Noninvasive PET Imaging of T cells. Trends in Cancer, 2018, 4, 359-373.	3.8	88
29	PET and SPECT imaging of melanoma: the state of the art. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 132-150.	3.3	29
30	Postsurgical Management of Differentiated Thyroid Cancer in China. Trends in Endocrinology and Metabolism, 2018, 29, 71-73.	3.1	10
31	Magnetic Targeting of Nanotheranostics Enhances Cerenkov Radiation-Induced Photodynamic Therapy. Journal of the American Chemical Society, 2018, 140, 14971-14979.	6.6	148
32	PET Imaging of Receptor Tyrosine Kinases in Cancer. Molecular Cancer Therapeutics, 2018, 17, 1625-1636.	1.9	35
33	Pulmonary metastases in children and adolescents with papillary thyroid cancer in China: prognostic factors and outcomes from treatment with 131l. Endocrine, 2018, 62, 149-158.	1.1	17
34	Circulating Tumor Cells Correlate with Clinicopathological Features and Outcomes in Differentiated Thyroid Cancer. Cellular Physiology and Biochemistry, 2018, 48, 718-730.	1.1	31
35	Metformin reduces glycometabolism of papillary thyroid carcinoma in vitro and in vivo. Journal of Molecular Endocrinology, 2017, 58, 15-23.	1.1	22
36	Thyroid autoimmune antibodies in patients with papillary thyroid carcinoma: a double-edged sword?. Endocrine, 2017, 58, 176-183.	1.1	25

#	Article	IF	Citations
37	Adefovir-Induced Hypophosphatemic Osteomalacia Mimicking Bone Metastases From Primary Hepatocarcinoma. Clinical Nuclear Medicine, 2017, 42, e405-e406.	0.7	2
38	A distinct serum metabolic signature of distant metastatic papillary thyroid carcinoma. Clinical Endocrinology, 2017, 87, 844-852.	1.2	33
39	Diagnostic Performance of 18F-FDG PET/CT in Papillary Thyroid Carcinoma with Negative 131I-WBS at first Postablation, Negative Tg and Progressively Increased TgAb Level. Scientific Reports, 2017, 7, 2849.	1.6	10
40	Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer. Theranostics, 2017, 7, 987-1001.	4.6	28
41	Dual time-point 18F-FDG PET/CT imaging with multiple metabolic parameters in the differential diagnosis of malignancy-suspected bone/joint lesions. Oncotarget, 2017, 8, 71188-71196.	0.8	5
42	Value of Tc-MDP SPECT/CT and F-FDG PET/CT scanning in the evaluation of malignantly transformed fibrous dysplasia. American Journal of Nuclear Medicine and Molecular Imaging, 2017, 7, 92-104.	1.0	3
43	Metastatic Malignant Fibrous Histiocytoma Infiltrating Sigmoid Colon. Clinical Nuclear Medicine, 2016, 41, 338-340.	0.7	1
44	Afamin promotes glucose metabolism in papillary thyroid carcinoma. Molecular and Cellular Endocrinology, 2016, 434, 108-115.	1.6	20
45	Circulating Long Non-Coding RNAs Act as Biomarkers for Predicting 1311 Uptake and Mortality in Papillary Thyroid Cancer Patients with Lung Metastases. Cellular Physiology and Biochemistry, 2016, 40, 1377-1390.	1.1	35
46	miRNA-106a directly targeting RARB associates with the expression of Na+/lâ^' symporter in thyroid cancer by regulating MAPK signaling pathway. Journal of Experimental and Clinical Cancer Research, 2016, 35, 101.	3.5	35
47	Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib. Oncology Reports, 2016, 36, 1576-1584.	1.2	21
48	Micro <scp>RNA</scp> s as a potential tool in the differential diagnosis of thyroid cancer: a systematic review and metaâ€analysis. Clinical Endocrinology, 2016, 84, 127-133.	1.2	18
49	Value of post-therapeutic 131I scintigraphy in stimulated serum thyroglobulin-negative patients with metastatic differentiated thyroid carcinoma. Endocrine, 2016, 51, 283-290.	1.1	10
50	Differential expression profiling of circulation microRNAs in PTC patients with non- 131 I and 131 I-avid lungs metastases: a pilot study. Nuclear Medicine and Biology, 2015, 42, 499-504.	0.3	22
51	Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors. European Journal of Endocrinology, 2015, 173, 399-408.	1.9	93
52	Comparison of SPET/CT, SPET and planar imaging using 99mTc-MIBI as independent techniques to support minimally invasive parathyroidectomy in primary hyperparathyroidism: A meta-analysis. Hellenic Journal of Nuclear Medicine, 2015, 18, 127-35.	0.2	46